CD274 and non-small cell lung carcinoma: At this time, remarking squamous NSCLC with low PD‐L1 expression (TPS 1%–49%) and no mutations, we investigated the efficacy and safety of regimens including molecularly targeted drugs, such as ICIs, by conducting a network meta‐analysis.